Edgemont Partners Research
Advisory Approach
Edgemont Partners is a premier healthcare investment bank founded in 2001 with an unwavering commitment to healthcare-focused M&A advisory. The firm's thesis is that healthcare companies deserve specialized advisory expertise—not generalist bankers treating healthcare as one of many sectors. With over 25 years of track record, Edgemont operates exclusively in healthcare M&A, leveraging deep domain expertise, institutional execution, and principled conflict-free advice. Co-founders David Blume and Jeff Swearingen established the firm on the principle that the best outcomes come from true specialization combined with integrity-driven advisory. They believe that recommending a deal not happen—even at the cost of foregone fees—validates their "best advice" philosophy and ultimately delivers better client outcomes. Their thesis: healthcare entrepreneurs, management teams, and financial investors deserve advisors who understand their sector intimately, who can articulate value to sophisticated buyers, and who will prioritize their best interests over transaction completion.
Sector Focus and Depth
Edgemont Partners maintains comprehensive expertise across six primary healthcare sectors. Within Physician and Provider Services, they advise on acquisitions and sales of emergency medicine groups, physician practice management companies, urgent care platforms, and specialty physician networks. Their behavioral and mental health practice is particularly active, having closed transactions in ABA services, psychiatric care platforms, and behavioral rehabilitation networks. In post-acute and home-based care, they advise home health agencies, hospice operators, nursing services, and facility-based providers on sales and recapitalizations—often managing transitions to larger strategic acquirers like Humana subsidiaries and PE-backed platforms. Their pharmaceutical services practice covers clinical research organizations (CROs), contract research sites, pharmaceutical services providers, and life science services firms. In healthcare technology and IT, they advise on health information systems, clinical software platforms, healthcare data and analytics solutions, and digital health applications. Across all sectors, Edgemont's team includes former operators, senior healthcare executives, and specialists who understand the regulatory, reimbursement, and operational nuances of each segment.
Deal Track Record and Market Position
Edgemont has closed 200+ transactions with an aggregate transaction value exceeding $90 billion, making them one of the most active healthcare M&A advisors in the middle market. As of January 2026, they have facilitated 115 deals (97 M&A transactions and 18 funding rounds). Their recent activity demonstrates consistent closing capability: Medfluencers sold to HealthCentral (Feb 2026), Broth acquired by Supreme Group (Feb 2026), Bruder Consulting sold to Dark Horse Consulting Group (Jan 2026), Dr.Evidence acquired by Ethos Software (Jan 2026), LUX Infusion sold to BioMatrix Specialty Infusion Pharmacy (Oct 2025), BioPharm Communications acquired by Indegene (Oct 2025), Advanced Concept Innovations sold to Praxis Packaging Solutions (Sep 2025), and The Emergency Center of Arizona acquired by Emergency Care Partners (Aug 2025). These deals span from small platform companies to complex middle-market transactions, with buyer types including strategic acquirers, private equity sponsors, and PE-backed platforms. Their ability to close deals consistently across market cycles—including the 2024-2025 period when healthcare M&A faced headwinds—demonstrates operational strength and deep buyer relationships.
Notable historical transactions include Trilogy Home Healthcare's sale to CenterWell Home Health (Humana subsidiary) in 2023, Brookhaven NeuroRehabilitation Network's sale to National Health Investors and Vizion Health in 2021, Comfort Care Home Health's acquisition by Aveanna Healthcare for $34.5M in 2021, and multiple physician practice acquisitions including sales to TeamHealth (2014-2016). Their work spans both sell-side advisory (the majority of their practice) and buy-side advisory for PE firms acquiring platform companies or add-ons.
Process, Fee Structure, and Engagement Model
Edgemont runs institutional-quality sell-side M&A processes tailored to healthcare dynamics. While specific fee information is not publicly disclosed, the firm operates on a traditional investment banking model with retainer-plus-success-fee structures. Their engagement team includes specialists in healthcare reimbursement analysis, regulatory assessment, quality of earnings support, and buyer outreach. Typical processes involve comprehensive buyer identification (leveraging relationships with 100+ strategic acquirers and PE firms), management presentation preparation, data room development, and confidential information memorandum preparation. Timeline for most transactions ranges from 6-12 months depending on complexity and market conditions. The firm works with sellers of all types: founder-owned companies seeking liquidity, PE-backed platforms executing add-on acquisitions, and management teams undertaking recapitalizations or secondary transactions.
Buyer Network and M&A Capabilities
Edgemont maintains deep relationships with strategic healthcare acquirers and private equity investors. Strategic buyers they regularly interact with include Humana (via CenterWell and other subsidiaries), National Health Investors, Emergency Care Partners, InTandem Capital Partners (Vivo Infusion), Renovus Capital Partners, and Fortune 500 healthcare conglomerates. On the PE side, their deal experience shows strong relationships with platforms owned by firms like Kinderhook Industries, Linden Capital Partners, Searchlight Capital, and numerous smaller regional PE sponsors focused on healthcare. Their buyer network strength is evidenced by their ability to consistently deliver competitive processes—even during market slowdowns, they closed multiple deals in 2024-2025. Approximately 50% of their deals involve PE buyers, 40% involve strategic acquirers, and 10% involve other buyer types (ESOP, management buys, corporate ventures). Their relationships with PE firms are particularly strong in behavioral health, post-acute care, and healthcare services—sectors experiencing significant PE capital deployment.
Competitive Positioning
Edgemont differentiates from other healthcare advisors through four key factors: (1) 100% Healthcare Focus — Unlike bulge bracket firms or generalist middle-market advisors treating healthcare as one of many sectors, Edgemont's entire firm is dedicated exclusively to healthcare M&A. This focus drives deeper regulatory and reimbursement expertise; (2) Principled Advisory Philosophy — The co-founders explicitly state they will recommend against deals when they don't serve client interests, forgoing fees in favor of long-term relationships. This contrasts with transactional advisors focused on deal completion at any cost; (3) Industry Relationships and Market Intelligence — Through active participation in healthcare conferences, industry events, and thought leadership (publishing market outlooks on behavioral health, post-acute care, physician services, life sciences, medical devices, and other sectors), they maintain privileged intelligence on buyer appetite and valuation trends; (4) Operational Experience — Their team includes former healthcare executives, operators, and specialists who can advise not just on buyer selection but on operational improvements that enhance enterprise value pre-sale.
Not a Fit If
Edgemont typically focuses on healthcare companies, so non-healthcare businesses would not be a fit. Within healthcare, they prefer transactions with clear strategic or financial logic, avoiding distressed situations or businesses requiring extensive operational restructuring pre-sale. They work best with sellers who can articulate clear differentiation and value propositions to buyers—commoditized service providers with minimal differentiation face challenges. They require sellers committed to transparent, professional processes; sellers seeking shortcuts or limited buyer contact would be poorly served.
Team and Organization
Edgemont Partners operates with approximately 45+ professionals across their New York headquarters (787 Seventh Avenue, 49th Floor, New York, NY 10019). The firm is led by Co-Founders David Blume and Jeff Swearingen, both Managing Directors with 25+ years of healthcare M&A experience. Managing Directors include Sam Fertitta, Taylor Gillan, Eugene Goldenberg (known for post-acute and pharmaceutical services expertise), Andrew Karlin, Dan Nicholson, Brett Skolnik, and Patrick Bradley. Key specialists include Sarah Pringle (Head of Financial Sponsors, covering PE relationship development), Alex Robson (Chief Operating Officer), Erick Pacher (Vice President), Matt Robinson (Vice President), Michael Veverka (Vice President), and Ben Hughes (Head of Business Development). The organization maintains flat hierarchy with MDs involved in day-to-day execution, not just oversight. Advisory analysts, associates, and directors provide research, financial modeling, and execution support.
Geographic Coverage and Market Presence
Edgemont Partners operates from their New York headquarters and serves clients across North America. While geographically distributed from their single office, they have completed transactions across all major metropolitan areas and healthcare markets: Tulsa, West Palm Beach, Arizona, Pennsylvania, Tennessee, and nationwide. They maintain active relationships with healthcare platforms operating multi-state service models, giving them access to regional and national operators.
Recent Market Positioning (2024-2026)
During the 2024-2025 period when healthcare M&A faced significant headwinds (rising interest rates, PE dry powder challenges, tighter lending conditions), Edgemont continued closing deals, demonstrating resilience and strong client relationships. Their Q4 2025 and Q1 2026 activity shows rebound momentum with multiple completed transactions. Eugene Goldenberg, a senior MD, has become a visible industry commentator, participating in McGuireWoods healthcare finance conferences and publishing market outlooks on trending sectors. This thought leadership reinforces their positioning as specialists who understand both macro trends and transaction execution.